A detailed history of Wells Fargo & Company transactions in Compugen LTD stock. As of the latest transaction made, Wells Fargo & Company holds 45,900 shares of CGEN stock, worth $83,997. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,900
Previous 42,900 6.99%
Holding current value
$83,997
Previous $110,000 30.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.68 - $2.52 $5,040 - $7,560
3,000 Added 6.99%
45,900 $77,000
Q1 2024

May 10, 2024

BUY
$1.75 - $2.95 $64,225 - $108,265
36,700 Added 591.94%
42,900 $110,000
Q4 2023

Feb 09, 2024

BUY
$0.53 - $2.0 $318 - $1,200
600 Added 10.71%
6,200 $12,000
Q1 2023

May 12, 2023

SELL
$0.68 - $1.11 $680 - $1,110
-1,000 Reduced 15.15%
5,600 $3,000
Q4 2022

Feb 13, 2023

BUY
$0.58 - $1.2 $290 - $600
500 Added 8.2%
6,600 $4,000
Q3 2022

Nov 14, 2022

SELL
$0.66 - $2.32 $1,320 - $4,640
-2,000 Reduced 24.69%
6,100 $5,000
Q4 2021

Feb 14, 2022

SELL
$4.09 - $7.16 $3,824 - $6,694
-935 Reduced 10.35%
8,100 $35,000
Q3 2021

Nov 15, 2021

SELL
$5.8 - $8.02 $5,800 - $8,020
-1,000 Reduced 9.97%
9,035 $54,000
Q2 2021

Aug 16, 2021

SELL
$6.87 - $9.16 $59,233 - $78,977
-8,622 Reduced 46.21%
10,035 $83,000
Q1 2021

May 13, 2021

BUY
$7.67 - $13.77 $83,610 - $150,106
10,901 Added 140.55%
18,657 $160,000
Q4 2020

Feb 09, 2021

BUY
$12.07 - $17.95 $37,742 - $56,129
3,127 Added 67.55%
7,756 $94,000
Q3 2020

Nov 05, 2020

SELL
$14.16 - $19.45 $498,304 - $684,464
-35,191 Reduced 88.38%
4,629 $76,000
Q2 2020

Aug 13, 2020

BUY
$6.97 - $17.12 $68,898 - $169,231
9,885 Added 33.02%
39,820 $599,000
Q1 2020

May 14, 2020

BUY
$5.79 - $11.83 $173,323 - $354,131
29,935 New
29,935 $217,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $159M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.